Cosmo Bio Co

Cosmo Bio Co Tax Expense

The Income Tax Expense of Cosmo Bio Co (3386.T) as of Oct 28, 2026 is 170.00 M JPY. In the previous year, Income Tax Expense was 99.00 M JPY — a change of 71.72% (higher).

Tax Expense

170.00 MJPY

YoY

71.72%

Last updated:

Income Tax Expense of Cosmo Bio Co is 2025 170.00 M JPY. Income Tax Expense of Cosmo Bio Co was 2024 99.00 M JPY. It decreases by 71.72% higher compared to the previous year.

The Cosmo Bio Co Tax Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tax Expense
Date
Tax Expense
Jan 1, 2018
125.00 M JPY
Jan 1, 2019
142.00 M JPY
Jan 1, 2020
307.00 M JPY
Jan 1, 2021
330.00 M JPY
Jan 1, 2022
238.00 M JPY
Jan 1, 2023
191.00 M JPY
Jan 1, 2024
99.00 M JPY
Jan 1, 2025
170.00 M JPY
The Cosmo Bio Co Tax Expense history
YEARTax ExpenseYoY
170.00 MJPY+71.72%
99.00 MJPY-48.17%
191.00 MJPY-19.75%
238.00 MJPY-27.88%
330.00 MJPY+7.49%
307.00 MJPY+116.20%
142.00 MJPY+13.60%
125.00 MJPY-16.11%
149.00 MJPY-16.76%
179.00 MJPY+13.29%
158.00 MJPY+20.61%
131.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmo Bio Co stock

Income Tax Expense of Cosmo Bio Co is 170.00 M JPY in 2025.

Income Tax Expense of Cosmo Bio Co changed from 99.00 M JPY to 170.00 M JPY, representing a 71.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Income Tax Expense Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

Tax expense represents the total income taxes owed. It reflects the company's tax obligations and effective tax rate.

Income Tax Expense's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Income Tax Expense's Cosmo Bio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Cosmo Bio Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Cosmo Bio Co